BACTERIAL EXPRESSION OF LYMPHOMA RNRNASE IMMUNOTOXIN

淋巴瘤核糖核酸酶免疫毒素的细菌表达

基本信息

  • 批准号:
    2867541
  • 负责人:
  • 金额:
    $ 10万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-04-15 至 1999-09-30
  • 项目状态:
    已结题

项目摘要

The objective of this project is to employ a bacterial high-level expression system to express recombinant ribonuclease of frog (Rana Pipiens) origin (rpRNase), either alone, or as a fusion protein with a humanized single chain antibody specific for B-cell lymphoma (rpRNase-hLL2scFv). Attempts to express rpRNase as recombinant protein were not successful because of its cytosolic toxicity in mammalian cells and its necessary requirement for an N-terminal pyroglutamyl residue to remain enzymatically active. The proposal suggests the production of rpRNase or rpRNase-hLL2scFv in E. coli as inclusion bodies containing an N-terminal Methionine. Strategies are developed to solubilize and renature the recombinant proteins which are post-translationally modified to resume a bioactive structure. The biological activities of the recombinant proteins in terms of RNase activity, inhibition or protein synthesis in cell-free system or in tissue culture will be studied. For the immunotoxin fusion protein, a cleavable peptide linker is incorporated to facilitate rpRNase release upon internalization. The bioactive recombinant rpRNase will be chemically conjugated to hLL2, and its anti-tumor effect, both in vitro and in vivo (in tumor-bearing mice), will be compared with that of rpRNase-hLL2scFv. PROPOSED COMMERCIAL APPLICATION: The development of an economic and efficient strategy to produce a bioactive recombinant rpRNase either alone or as fusion protein to a B-cell lymphoma specific single chain antibody. The recombinant rpRNase can be used as an anti-tumor agent for sensitize tumors or as immunotoxin conjugated to antibodies of different tumor specificities. The fusion protein can be used for the treatment of B-cell lymphoma.
本研究的目的是利用细菌高水平表达系统表达蛙源重组核糖核酸酶(rpRNase),无论是单独表达还是与B细胞淋巴瘤特异性人源化单链抗体(rpRNase-hLL 2scFv)融合表达。 由于rpRNase在哺乳动物细胞中的胞质毒性以及其保持酶活性所必需的N-末端焦谷氨酰残基的需要,将rpRNase表达为重组蛋白的尝试没有成功。 建议在E.大肠杆菌中的包涵体含有一个N-末端甲基。 开发了溶解和复性重组蛋白的策略,所述重组蛋白经后修饰以恢复生物活性结构。 将研究重组蛋白在无细胞系统或组织培养中的RNA酶活性、抑制或蛋白质合成方面的生物活性。 对于免疫毒素融合蛋白,掺入可裂解肽接头以促进内化后rpRNase释放。 生物活性重组rpRNase将与hLL 2化学缀合,并且其体外和体内(在荷瘤小鼠中)的抗肿瘤效果将与rpRNase-hLL 2scFv的抗肿瘤效果进行比较。拟定商业应用:开发一种经济有效的策略来生产单独的或作为与B细胞淋巴瘤特异性单链抗体的融合蛋白的生物活性重组rpRNase。该重组rpRNase可用作致敏肿瘤的抗肿瘤剂或用作与不同肿瘤特异性的抗体缀合的免疫毒素。 该融合蛋白可用于治疗B细胞淋巴瘤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHUI-ON LEUNG其他文献

SHUI-ON LEUNG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHUI-ON LEUNG', 18)}}的其他基金

MOLECULAR ENGINEERING OF MONOCLONAL ANTIBODIES FOR THE MANAGEMENT OF CANCER
用于癌症治疗的单克隆抗体分子工程
  • 批准号:
    6300387
  • 财政年份:
    2000
  • 资助金额:
    $ 10万
  • 项目类别:
MOLECULAR ENGINEERING OF MONOCLONAL ANTIBODIES FOR THE MANAGEMENT OF CANCER
用于癌症治疗的单克隆抗体分子工程
  • 批准号:
    6102689
  • 财政年份:
    1999
  • 资助金额:
    $ 10万
  • 项目类别:
MOLECULAR ENGINEERING OF MONOCLONAL ANTIBODIES FOR THE MANAGEMENT OF CANCER
用于癌症治疗的单克隆抗体分子工程
  • 批准号:
    6269481
  • 财政年份:
    1998
  • 资助金额:
    $ 10万
  • 项目类别:
MOLECULAR ENGINEERING OF MONOCLONAL ANTIBODIES FOR THE MANAGEMENT OF CANCER
用于癌症治疗的单克隆抗体分子工程
  • 批准号:
    6237201
  • 财政年份:
    1997
  • 资助金额:
    $ 10万
  • 项目类别:
ENGINEERING A UNIQUE CONJUGATION SITE ON AB LIGHT CHAIN
在 AB 轻链上设计独特的结合位点
  • 批准号:
    2106179
  • 财政年份:
    1994
  • 资助金额:
    $ 10万
  • 项目类别:
HUMANIZED ANTIBODY (MA5) FOR BREAST CANCER TREATMENT
用于乳腺癌治疗的人源化抗体 (MA5)
  • 批准号:
    3493545
  • 财政年份:
    1993
  • 资助金额:
    $ 10万
  • 项目类别:
MOLECULAR ENGINEERING OF MONOCLONAL ANTIBODIES FOR THE MANAGEMENT OF CANCER
用于癌症治疗的单克隆抗体分子工程
  • 批准号:
    5209123
  • 财政年份:
  • 资助金额:
    $ 10万
  • 项目类别:

相似国自然基金

牛蛙(Rana catesbeiana)皮肤抗菌肽基因克隆、改造与高效表达
  • 批准号:
    30571416
  • 批准年份:
    2005
  • 资助金额:
    26.0 万元
  • 项目类别:
    面上项目

相似海外基金

Evaluating immunotoxic effects of exposure to microplastics on North American wood frogs (Rana sylvatica) during development
评估北美林蛙(Rana sylvatica)在发育过程中暴露于微塑料的免疫毒性影响
  • 批准号:
    580818-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 10万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
CAREER: Investigating Host Response in the Pathogenesis of FV3 (Ranavirus sp) in Wood Frogs, Rana sylvatica (Lithobates sylvaticus)
职业:研究林蛙 (Lithobates sylvaticus) FV3(蛙病毒属)发病机制中的宿主反应
  • 批准号:
    2041443
  • 财政年份:
    2021
  • 资助金额:
    $ 10万
  • 项目类别:
    Continuing Grant
Identification of novel antimicrobial peptides in American bullfrog, Rana catesbeiana, tadpoles as potential antibiotic-alternatives for the poultry industry
鉴定美国牛蛙、林蛙、蝌蚪中的新型抗菌肽作为家禽业的潜在抗生素替代品
  • 批准号:
    565004-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 10万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Conserving species in a dynamic world: prioritizing conservation land for an amphibian (Rana aurora) using a life stage, multi-species occupancy distribution modeling approach
在动态世界中保护物种:使用生命阶段、多物种占用分布建模方法优先考虑两栖动物(极光蛙)的保护土地
  • 批准号:
    517840-2017
  • 财政年份:
    2019
  • 资助金额:
    $ 10万
  • 项目类别:
    Vanier Canada Graduate Scholarship Tri-Council - Doctoral 3 years
The Dynamic Regulation of RNA Metabolism, Processing, and Stability in Rana sylvatica, a Multi-Factorial Model of Animal Adaptation
林蛙 RNA 代谢、加工和稳定性的动态调节,动物适应的多因素模型
  • 批准号:
    503942-2017
  • 财政年份:
    2019
  • 资助金额:
    $ 10万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
The Dynamic Regulation of RNA Metabolism, Processing, and Stability in Rana sylvatica, a Multi-Factorial Model of Animal Adaptation
林蛙 RNA 代谢、加工和稳定性的动态调节,动物适应的多因素模型
  • 批准号:
    503942-2017
  • 财政年份:
    2018
  • 资助金额:
    $ 10万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
How does Rana virus as emerging pathogens in amphibians spread?
林蛙病毒作为两栖动物中的新兴病原体如何传播?
  • 批准号:
    18K05692
  • 财政年份:
    2018
  • 资助金额:
    $ 10万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Conserving species in a dynamic world: prioritizing conservation land for an amphibian (Rana aurora) using a life stage, multi-species occupancy distribution modeling approach
在动态世界中保护物种:使用生命阶段、多物种占用分布建模方法优先考虑两栖动物(极光蛙)的保护土地
  • 批准号:
    517840-2017
  • 财政年份:
    2018
  • 资助金额:
    $ 10万
  • 项目类别:
    Vanier Canada Graduate Scholarship Tri-Council - Doctoral 3 years
Identification of components in the thyroid hormone-induced molecular memory of Rana catesbeiana
林蛙甲状腺激素诱导的分子记忆成分的鉴定
  • 批准号:
    514371-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 10万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Conserving species in a dynamic world: prioritizing conservation land for an amphibian (Rana aurora) using a life stage, multi-species occupancy distribution modeling approach
在动态世界中保护物种:使用生命阶段、多物种占用分布建模方法优先考虑两栖动物(极光蛙)的保护土地
  • 批准号:
    517840-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 10万
  • 项目类别:
    Vanier Canada Graduate Scholarship Tri-Council - Doctoral 3 years
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了